- Castleman disease (CD)
- Langerhans cell histiocytosis
- Lymphoma
- Rosai-Dorfman disease (RDD)
- Waldenstrom macroglobulinemia
Joshua Daniel Brandstadter, MD, PhD, MSc
About me
- Director, Clinical Research, Center for Cytokine Storm Treatment & Laboratory
- Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
- Instructor A of Medicine (Hematology-Oncology)
Dr. Joshua Brandstadter is a physician-scientist who cares for patients with lymphoma and rare blood disorders, particularly Castleman Disease and histiocytic disorders. In addition to his clinical work, Dr. Brandstadter pursues laboratory-based translational research and serves as Director of Clinical Research for the Center for Cytokine Storm Treatment & Laboratory.
My education and training
- Duke University Medical CenterMedical School
- University of Pennsylvania Health SystemResidency
- University of Pennsylvania Health SystemFellowship
Spoken languages
Reviews
Insurance accepted
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Qualifications and experience
- Hematology, 2023
- Internal Medicine, 2018
- American Society of Hematology, International
- American Society of Transplantation and Cellular Therapy, International
- Castleman Disease Collaborative Network, International
- Uplifting Athletes, National
- Blood cancer care
All conditions and treatments
Research
Publications
McHugh K, Huang Y, Austin B, Borys L, Irvine AH, Alapat DV, Bagg A, Chadburn A, Lechowicz MJ, Lim MS, Srkalovic G, van Rhee F, Fajgenbaum DC, Zhang L, Brandstadter JD Idiopathic Multicentric Castleman Disease Unresponsive to One IL-6 Inhibitor May Respond to Another IL-6 Inhibitor , Blood Advances: 2026
Brandstadter JD, Meili S, Zinski J, Cheng HW, Laczko D, Gonzalez MV, George SS, Lim MS, Bagg A, Stanossek Y, Onder L, Lϋtge M, De Martin A, Austin B, Mumau M, Forsyth KS, Pillai V, Ferreira A, Aster JC, Nasta S, Ludewig B, Fajgenbaum DC, Maillard I Vascular smooth muscle cell abundance is a hallmark of Castleman Disease , JCI Insight: 2026
Gonzalez MV, Wang K, Zinski J, Mumau MD, Forsyth KS, Irvine AH, Brandstadter J, Guzman SG, Zhang L, Pierson SK, Austin B, Fajgenbaum DC Clusterin expression and germinal center morphometry help distinguish idiopathic multicentric castleman disease from select lymphadenopathies , Front Immunol, 17: 2026
Austin B, Pierson SK, Dacus KC, Sarmiento Bustamante M, Shyamsundar S, Borys L, McHugh K, Irvine A, Jo Y, Bagg A, Lechowicz M, Alapat D, Chadburn A, Lim MS, Srkalovic G, van Rhee F, Fajgenbaum DC, Brandstadter JD Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab , Pediatric Blood Cancer: 2026,e70702
Brandstadter JD, Lurain K, Nasta SD, and Fajgenbaum DC Chapter 59: Castleman Disease and Rosai-Dorfman-Destombes Disease , Classical Hematology: 2026,601
Shyamsundar S, Sarmiento Bustamante M, Borys L, Lim MS, Bagg A, Lechowicz MJ, Alapat D, Chadburn A, Srkalovic G, van Rhee F, Austin B, Brandstadter JD, Fajgenbaum DC Breast-implant associated unicentric castleman disease: a case report , Current Problems in Cancer Case Reports, 21: 2026,100404
Laczko D, Pillai V, Frank D, Brandstadter JD, Fajgenbaum DC How I diagnose Castleman disease , American Journal of Clinical Pathology, 165(3): 2026,aqaf147
Kurz L, Lutge M, De Martin A, Cheng H-W, Bugar E, Stanossek Y, Meili S, Brandstadter JD, Maillard I, Onder L, Ludewig B A common progenitor gives rise to fibroblastic reticular cells and vascular smooth muscle cells in murine lymph nodes , Journal of Experimental Medicine, 2(223): 2026,e20242300
McHugh K, Huang Y, Austin B, Borys L, Irvine A, Alapat D, Bagg A, Chadburn A, Lechowicz MJ, Lim M, Srkalovic G, van Rhee F, Fajgenbaum D, Zhang L, Brandstadter J Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor , American Society of Hematology Annual Meeting, Orlando, FL: 2025
Steven Rowe, Mariam Goubran, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Bridget Austin, Kathleen McNicholas, Marley Blommers, Junyan Shi, Lisa K Peterson, Lusia Sepiashvili, Andre Mattman, Joshua D Brandstadter, David C Fajgenbaum, Luke Y C Chen Ferritin, C-Reactive Protein, and Soluble CD25 Distinguish TAFRO From HLH , Am J Hematol: 2025